GOVX — GeoVax Labs, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 832489 ·
Last close
$2.01
Market Cap
$1.09M
52W High
$270.60
52W Low
$1.50
ADV30
283,086
Next earnings
—
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,174,469 -4,156,001 3,424,359 2,150,946 2,276,792
Jun 2026 0 — -4,442,072 -4,426,578 4,642,757 3,143,422 2,882,056
Mar 2026 0 — -5,272,881 -5,261,921 2,982,433 1,271,762 2,488,663
Dec 2025 0 — -4,441,756 -4,418,423 6,341,868 3,085,741 2,516,736

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,369,715
Investing CF
$0
Financing CF
$18,419,275
CapEx
$-27,612
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-20.09
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-160,509,351
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-20,452,290
Pretax Income TTM
$-20,425,836
Interest Exp TTM
$0
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-20,470,740
Free Cash Flow
$-10,819,786
Enterprise Value
$-2,193,895
Total Cash
$3,143,422
Total Debt
$323,141
Shares Out
544,453
Trailing EPS
$-15.03
Book Value
$53.00
ROE
-891.6%
ROA
-256.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,489,145 -21,639,047 -21,464,771 6,341,868 2,516,736 3,825,132 -21,473,969
Dec 2024 3,954,576 -25,144,280 -24,992,296 8,155,867 3,107,332 5,048,535 -24,675,511
Dec 2023 0 -26,742,939 -25,966,762 9,283,219 3,519,881 5,763,338 -25,173,639
Dec 2022 81,526 -14,028,564 -14,021,125 31,347,928 4,747,894 26,600,034 -19,030,208

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-20,425,836
OpCashFlow TTM
—
Assets (Latest)
$4,642,757
Forward EPS
$-0.86

Peers — same industry

TickerNameMarket CapLastDaily %
ELAB PMGC Holdings Inc. $1.20M $1.48 —
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
OGEN ORAGENICS INC $947.5K $0.21 —
ISCO International Stem Cell CORP $1.28M $0.16 —
ATXI AVENUE THERAPEUTICS, INC. $922.6K $0.28 —

News headlines (Yahoo Finance, 1h cache)

GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
2026-11-09 13:30 · Yahoo
Update - GeoVax Enters Into $1 Million Revolving Loan Agreement
2026-10-27 12:30 · Yahoo
GeoVax Enters Into $1 Million Revolving Loan Agreement
2026-10-26 21:27 · Yahoo
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
2026-10-06 12:37 · Yahoo
GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
2026-09-29 12:37 · Yahoo
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
2026-09-21 12:37 · Yahoo
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
2026-09-14 12:37 · Yahoo
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
2026-09-10 12:37 · Yahoo
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
2026-09-09 13:00 · Yahoo
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
2026-08-25 12:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.